IGFBP7 is a member of the insulin superfamily of growth promoting peptides and is one of the most abundant and common growth factor polypeptides. IGFBPs are a class of secreted proteins that is able to interact with many ligands other than IGFs.1
Currently, IGFBP-7 has been used as an early diagnosis and prognostic marker for acute renal insufficiency (AKI). IGFBP-7, and TIMP-2 concentrations in the urine of children after receiving injections of contrast medium increased faster than SCr. The combination of IGFBP-7 and TIMP-2 was better than either analyte alone (the specificity was 80.0%, and the sensitivity was 81.2%).2 Based on the results of two studies, the urine compound of TIMP-2 and IGFBP-7 became US Food and Drug Administration (FDA)-approved biomarker for risk assessment of AKI in ICU patients.1
IGFBP-7 has also been proposed as a potential prognostic biomarker in heart failure (HF). It provided prognostic information incremental to clinical variables, NT-proBNP, and hsTnT.3
RESOURCES
- Wang S, Chi K, Wu D, Hong Q. Insulin-Like Growth Factor Binding Proteins in Kidney Disease. Front Pharmacol. 2021 Dec 22;12:807119. doi: 10.3389/fphar.2021.807119. PMID: 35002740; PMCID: PMC8728008.
- Sun Q, Kang Z, Li Z, Xun M. Urinary NGAL, IGFBP-7, and TIMP-2: novel biomarkers to predict contrast medium-induced acute kidney injury in children. Ren Fail. 2022 Dec;44(1):1201-1206. doi: 10.1080/0886022X.2022.2075277. PMID: 36120960; PMCID: PMC9518296.
- Adamson C, Welsh P, Docherty KF, de Boer RA, Diez M, Drożdż J, Dukát A, Inzucchi SE, Køber L, Kosiborod MN, Ljungman CEA, Martinez FA, Ponikowski P, Sabatine MS, Morrow DA, Lindholm D, Hammarstedt A, Boulton DW, Greasley PJ, Langkilde AM, Solomon SD, Sattar N, McMurray JJV, Jhund PS. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF. JACC Heart Fail. 2022 Oct 20:S2213-1779(22)00571-6. doi: 10.1016/j.jchf.2022.09.004. Epub ahead of print. PMID: 36592046.
